Full Text View
Tabular View
No Study Results Posted
Related Studies
Comparison Between Type A Botulinum Toxin Injection and Corticosteroid Injection in the Treatment of Tennis Elbow
This study is currently recruiting participants.
Study NCT00395616   Information provided by E-DA Hospital
First Received: November 2, 2006   No Changes Posted

November 2, 2006
November 2, 2006
November 2006
 
  • WHOQOL-BREF
  • visual analogue scale for pain
  • grip strength
Same as current
No Changes Posted
 
 
 
Comparison Between Type A Botulinum Toxin Injection and Corticosteroid Injection in the Treatment of Tennis Elbow
 

Humeral lateral epicondylitis or tennis elbow is a common painful elbow disorder. The cause of tennis elbow is the chronic overload of bone-tendon junction. High prevalence of tennis elbow has a direct impact on the workplace productivity and quality of life. Steroid injection is the very few methods proved to have short-term efficacy in tennis elbow treatment, but it has potential adverse effects like tendon rupture. Temporary paralysis of muscle after botulinum toxin injection may reduce the physical demands and facilitate the normal repair mechanism during recovery. Preliminary studies suggested that botulinum toxin injection is effective in treating tennis elbow. The objective of this study is to compare the effects of botulinum toxin injection with corticosteroid injection in tennis elbow treatment.

 
 
Interventional
Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment
  • Type A Botulinum Toxin
  • Tennis Elbow
Drug: Botox (drug)
 
 

*   Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
 
Recruiting
40
 
 

Inclusion Criteria:

  • Pain at the lateral epicondyle of the elbow
  • Tenderness at the lateral epicondyle of the elbow
  • Pain on resisted extension of the wrist

Exclusion Criteria:

  • Local injection of steroid within 3 months
  • Previous elbow trauma or operations
  • Pregnancy
  • Systemic neuromuscular disorders such as myasthenia gravis
Both
20 Years to 80 Years
No
Contact: Yu-Ching Lin, MD 886-7-6150011 ext 2367 yuchinglin2003@yahoo.com.tw
Taiwan
 
NCT00395616
 
e120537192
E-DA Hospital
 
Study Chair: Yu-Ching Lin, MD E-Dah Hospital, Kaohsiung, Taiwan
E-DA Hospital
November 2006

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP